Clinical Trial Update: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate [Phase 4]

View source ↗

Summary

Phase 4 RESOunD trial on satisfaction after discontinuing dimethyl fumarate in multiple sclerosis. The study was terminated and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)
• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: EMD Serono | Conditions: Multiple Sclerosis | Phase 4 | Status: TERMINATED | Results posted: 2017-01-23